At Sanarus Technologies we think that women deserve a better outcome.
Sanarus developed, patented, and tested a proprietary minimally invasive cryoablation system, the Visica® 2 Treatment System. The Visica 2 Treatment System is an image-guided device that freezes the tumor, thereby destroying it and preventing regrowth. The procedure, known as the Visica® Procedure, offers patients a non-surgical alternative to treatments such as lumpectomy and is available at participating centers nationwide. To find a physician near you who specializes in this procedure, please contact us at 800-909-3060 or.
In a 5-year multicenter study funded by the National Cancer Institute and sponsored by the Alliance for Clinical Trials in Oncology, cryoablation with the Visica 2 Treatment System was shown to be 100% effective for complete ablation of invasive ductal breast cancer tumors <1.0 cm. Results from this breast cancer study (ACOSOG Z1072), which included a 5-year follow-up, were published in the Annals of Surgical Oncology. The Visica 2 Treatment System was the exclusive device used in the Z1072 study and showed cryoablation effective in 92% of the targeted lesions.4
The Visica 2 Treatment System is FDA 510 (k) cleared and has been used in over 4,000 patients, to date. Over 20 papers have been published about cryoablation with the Visica 2 Treatment System, showing it to be a viable alternative to surgical resection.
A message from our Chairman...
"Being a woman, I understand that this may be a very difficult time for you and your family. That's why we are committed to give you the information and education you need to make an informed decision. We welcome you to contact us today with your questions and we will do our best to help you."
What's it like to receive a diagnosis you didn't expect?
Watch BJ Hardman, chairman and CEO of Sanarus Technologies, as she goes from diagnosis through treatment with the Visica 2 Treatment System.